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The increase of life expectancy has led to the increase of age-related diseases such 
as osteoporosis. Osteoporosis is characterized by bone weakening promoting the 
occurrence of fractures with defective bone regeneration. Men aged over 50 have a 
prevalence for osteoporosis of 20%, which is related to a decline in sex hormones 
occurring during andropause or surgical orchidectomy. As we previously demonstrated 
in a mouse model for menopause in women that treatment with the neurohypophyseal 
peptide hormone oxytocin (OT) normalizes body weight and prevents the development 
of osteoporosis, herein we addressed the effects of OT in male osteoporosis. Thus, 
we treated orchidectomized mice, an animal model suitable for the study of male 
osteoporosis, for 8 weeks with OT and then analyzed trabecular and cortical bone 
parameters as well as fat mass using micro-computed tomography. Orchidectomized 
mice displayed severe bone loss, muscle atrophy accompanied by fat mass gain as 
expected in andropause. Interestingly, OT treatment in male mice normalized fat mass 
as it did in female mice. However, although OT treatment led to a normalization of 
bone parameters in ovariectomized mice, this did not happen in orchidectomized mice. 
Moreover, loss of muscle mass was not reversed in orchidectomized mice upon OT 
treatment. All of these observations indicate that OT acts on fat physiology in both sexes, 
but in a sex specific manner with regard to bone physiology.
Keywords: orchidectomy, bone, adipose tissue, male, female, mice
introduction
Life expectancy continually increases in industrialized countries and is linked to aging-associated 
phenotypes such as a decrease in hormonal levels, lean and bone mass, as well as gain in fat mass. 
Along with aging-associated diseases defined as a major cause of morbidity and mortality, osteoporosis 
can be found essentially associated to a severe decrease in circulating estrogens due to menopause in 
women (1). Although with lower frequency than in women, the osteoporosis in men aged over 50 has a 
prevalence of 20% and is a relatively common burden with treatments less defined than in women (2).
Osteoporosis, defined by the deterioration of bone density and microarchitecture leading to bone 
fragility (3), is a major public health problem with 6.3 million of cases expected in 2050 (4). Besides 
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substantial financial costs, this disease leads to a deleterious life 
quality with a significant decrease in mobility up to the loss of 
autonomy, a susceptibility to other diseases such as osteoarthritis 
and obesity, and finally a significant increase in morbidity and 
mortality, especially in the course of the year following a hip 
fracture. Osteoporosis in men is less well known, but seems to be 
also associated with a decrease in sex hormone levels (androgens), 
particularly testosterone, and is aggravated by environmental 
factors such as nutrition and physical inactivity (2). It is difficult 
to anticipate the onset of osteoporosis in men (5), except after 
surgical removal of the testis (orchidectomy), for example, in case 
of prostate cancer treatment to reduce testosterone level, which 
leads to a drop in the level of circulating androgens (6). In these 
cases, preventive postoperative treatments can be provided to limit 
the development of osteoporosis. As for women, a decrease of sex 
hormones can also cause weight gain, behavioral changes, and 
muscle wasting in men (5).
Osteoporosis may affect trabecular or cortical bone associated 
with different types of fractures (7, 8). The strength and integrity of 
the bone depend on the balance between resorption by osteoclasts 
and bone formation by osteoblasts (9, 10). The decrease of bone 
mass, which occurs during osteoporosis, implies an acceleration 
of the “bone turnover” with an imbalance between resorption and 
formation in favor of bone resorption (11, 12).
In addition to bone loss, osteoporosis is associated with a gain 
in bone marrow adiposity due to the formation of adipocytes, 
at the expense of osteoblasts, both derived from a common 
progenitor: the mesenchymal stem cell. Adiposity is also con-
nected to the prevalence of bone fracture in osteoporosis (13). 
The adipocyte/osteoblast balance is essential for bone homeostasis, 
as it determines (1) the amount of essential osteoblasts for bone 
formation and (2) the secretion of adipokines involved in bone 
metabolism. We previously characterized the major role of this 
balance in the pathophysiology of osteoporosis, which is controlled 
by a circulating hormone, namely oxytocin (OT). In  vitro, the 
treatment of mesenchymal stem cells with O promotes the forma-
tion of osteoblasts and inhibits adipogenesis (14). In addition, 
we showed an inverse correlation between OT circulating levels 
and the occurrence of osteoporosis (14–16) on a small cohort of 
post-menopausal women first, and then on a larger cohort from 
a European prospective multicenter study (OPUS). Finally, we 
demonstrated that treatment of ovariectomized mice, an animal 
model mimicking menopause in women, by daily injections of OT 
(1 mg/kg/day) prevented and reversed the osteoporotic phenotype. 
Indeed, both OT preventive and curative treatments led to nor-
malization of bone parameters (morphometric and mechanical), 
to a decrease of bone marrow adiposity and, interestingly, to a 
normalization in weight gain induced by ovariectomy (17).
Oxytocin belongs to the family of pituitary hormones and 
regulates the function of peripheral organs including the mam-
mary glands and smooth muscle of the uterus. Due to this property, 
it has commonly been used in other medical obstetrics without 
significant side effects (18). Thus, OT emerges as a promising 
molecule in the treatment of osteoporosis.
Herein, we daily injected orchidectomized male mice with 
1 mg/kg of OT for 8 weeks to analyze its effect on male osteopo-
rosis. We previously used this protocol with success to reverse 
the bone phenotype in ovariectomized female mice (17, 19). 
Analysis of treated mice demonstrated that OT did not restore 
the bone loss and muscle atrophy in orchidectomized male 
mice. These results demonstrated a sex-dependent efficiency 
of OT on bone remodeling following gonadectomy that might 
be linked to the difference in sexual hormones between male 
and female.
Materials and Methods
animals
The experiments were conducted in accordance with the French 
and European regulations for the care and use of research animals 
and were approved by the local experimentation committee. 
Animals were maintained under constant temperature (21 ± 2°C) 
and 12:12-hour light–dark cycles, with ad  libitum access to 
standard chow diet and water. Ten-week-old C57Bl/6J mice were 
randomized and subjected to bilateral orchidectomy, ovariectomy 
or sham surgery by the manufacturer (Charles River Laboratories). 
For sham-operated mice, the testis or ovaries were exteriorized but 
replaced intact. Two weeks after surgery, orchidectomized (ORX), 
ovariectomized (OVX), or sham groups of mice (n = 12) were 
intra-peritoneally injected with vehicle (Ve, NaCl 0.9%) or OT 
(1 mg/kg) on a daily basis and over 8 weeks.
Micro-computed Tomography
Trabecular bone microarchitecture of the distal femoral metaphy-
sis was analyzed using the high-resolution SkyScan-1076 X-ray 
micro-computed tomography system (SkyScan). Femora were 
scanned after necropsy using the same parameters: 9 μm of pixel 
size, 49 kV, 0.5 mm thick aluminum filter, and 0.5° of rotation 
step. Calculation of femur trabecular bone parameters (Bone 
Volume/Total Volume: BV/TV) following 3D morphometric 
parameters (Bone ASBMR nomenclature) were performed on 
0.9 mm of femur length from the distal growth plate excluding 
the cortical bone. Analysis of cortical bone was performed using 
the same parameters. Cortical cross-sectional area (CSA) was 
determined on a transversal section localized at the mid-length 
of the femoral shaft.
Adipose tissue quantification was carried out using a 
SkyScan-1178 X-ray micro-computed tomography system. Mice 
were anesthetized and scanned using the same parameters: 
104 μm of pixel size, 49 kV, 0.5 mm thick aluminum filter, and 
0.9° of rotation step. Total adipose tissue volume was determined 
between the lumbar vertebra 1 (L1) and the caudal vertebra 4 
(C4), whereas intra-abdominal and subcutaneous adipose tissues 
areas were measured on one section at the lumbar 5 (L5) level. 
3D reconstructions and analysis of bone parameters and adipose 
tissue areas or volumes were performed using NRecon and CTAn 
software (SkyScan).
Plasma Measurements
Blood was sampled by intracardiac puncture from anesthetized 
animals and plasma was stored at −80°C. Procollagen I N-Terminal 
propeptide (PINP, USCN) or Cross Linked C-Telopeptide of Type 
I Collagen (CTXI, USCN) plasma levels was measured using an 
ELISA kit as per the manufacturer’s instructions.
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Table 2 | MicrocT analysis of femora trabecular and cortical bone parameters.
Mice group   sham-Ve  
   (n = 12)
sham OT  
1 mg/kg (n = 12)
   OrX Ve  
   (n = 12)
OrX OT  
1 mg/kg (n = 12)
Trabecular bone
Distal femoral metaphysis BV/TV (%) 15.4 ± 1.2 11.9 ± 1.2 3.2 ± 0.3a 3.1 ± 0.3a
Tb. Th. (μm) 69 ± 1 63 ± 2a 65 ± 1a 62 ± 1a
Tb. N. (mm−1) 2.2 ± 0.1 1.9 ± 0.1 0.5 ± 0.04a 0.5 ± 0.04a
Tb. Sp. (μm) 238 ± 9 247 ± 6 532 ± 23a 528 ± 16a
cortical bone
Mid-femur diaphysis CSA (mm2) 1.04 ± 0.08 0.97 ± 0.06a 0.83 ± 0.04a 0.83 ± 0.04a
Control (Sham) and ORX mice were submitted to daily injections of OT or Ve for 8 weeks starting 2 weeks after surgery. Detailed analysis of trabecular parameters was performed on 
the distal metaphysis of femora and on the mid-femur diaphysis for cortical bone parameters. Bone volume/total volume (BV/TV), trabecular thickness (Tb. Th), trabecular spacing 
(Tb. Sp), trabecular number (Tb. N), and cortical cross-sectional area (CSA) are reported in the Table 1. 
ap < 0.05 vs. Sham-Ve (n = 12 mice/group). Data are represented as mean ± SEM.
isolation and analysis of rna
Total RNA was extracted using a TRI-Reagent kit as per the 
manufacturer’s instructions. For total bone RNA extraction, 
humeri were homogenized using an Ultra Turrax homogenizer 
and samples were then processed as per the TRI-Reagent extraction 
protocol. Two micrograms of total RNA, digested with DNAse 
I (Promega), were subjected to reverse transcription-polymerase 
chain reaction (RT-PCR) analysis as previously described (20). 
Quantitative PCR assays were run using an ABI Prism 7,000 real-
time PCR machine (PerkinElmer Life and Analytical Sciences). 
The final reaction volume was 20 μl, including 100 nM of specific 
primers, 20 ng of reverse-transcribed RNA, and 10 μl of SYBR 
Green master mix (Applied Biosystems). Quantitative PCR 
conditions were as follows: 2 min at 50°C; 10 min at 95°C; and 40 
cycles of 15 s at 95°C, 1 min at 60°C. The expression of genes was 
normalized to the expression of two housekeeping genes, 36B4 and 
hprt. Gene expression was quantified using the comparative −ΔCt 
method. The oligonucleotides for each target of interest, designed 
using Primer Express software (PerkinElmer Life and Analytical 
Sciences), are shown (forward and reverse) in Table 1.
statistical analyses
Data are expressed as mean values ±SEM and was analyzed using 
the two-tailed Student’s t-test. Differences were considered statisti-
cally significant at p ≤ 0.05.
Table 1 | sequence of primers used for gene expression analysis.
Target gene Forward reverse
RANKL GGAACTGCAACACATTGTGGG GCCTTCCATCATAGCT 
GGAGC
OPG TCCGGCGTGGTGCAA AGAACCCATCTGGACA 
TTTTTTG
Tracp TGCCTACCTGTGTGGACATGA CACATAGCCCACACCG 
TTCTC
Collagen 1 
alpha 1
GCGAAGGCAACAGTCGCT CTTGGTGGTTTTGTATT 
CGATGAC
Osteocalcin CCACCCGGGAGCAGTGT CTAAATAGTGATACCGT 
AGATGCGTTTG
Hprt GCCTAAGATGAGCGCAAGTTGA AGGCAGATGGCCACA 
GGACTA
36B4 TCCAGGCTTTGGGCATCA CTTTATCAGCTGCACAT 
CACTCAGA
results
Oxytocin Treatment does not restore bone 
Parameters in Orchidectomized Mice
We analyzed bone parameters upon OT treatment in orchidec-
tomized (ORX) and ovariectomized (OVX) mice, animal models 
for male and female osteoporosis, respectively. Two weeks post-
surgery, controls (male or female Sham) and ORX or OVX mice 
were daily injected with OT at a 1 mg/kg dose or vehicle (Ve, NaCl 
0.9%). After 8 weeks of treatment, trabecular and cortical bone 
parameters were analyzed using high-resolution micro-computed 
tomography (MicroCT). We confirmed our previous observations 
showing that OT treatment restored bone architecture of OVX 
mice (14, 17). As expected in ORX mice, orchidectomy induced a 
dramatic trabecular bone loss evidenced by the significant decline 
in BV/TV, trabecule thickness (Tb. Th.), and trabecule number 
(Tb. N.) as well as by an increase in the trabecule spacing (Tb. 
Sp.) compared to the Sham group (Table  2). In a similar way, 
cortical bone was also affected upon orchidectomy as depicted 
by the significant decrease of mid-diaphysis cortical CSA as 
shown in Table 2. In contrast to OVX mice, none of both cortical 
and trabecular parameters were restored in ORX mice upon OT 
treatment for 8  weeks as observed in Figure  1. In parallel, we 
quantified various bone remodeling markers in plasma from Sham 
and ORX mice treated with OT or vehicle. Regarding bone forma-
tion, neither orchidectomy nor OT injection modified its activity 
according to the plasma level of PINP (Figure 2A). In terms of 
bone resorption, we measured a significant increase in the level 
of CTXI in ORX mice, which was not significantly modified upon 
OT treatment (Figure 2B).
OT Treatment does not significantly impact the 
expression of bone Molecular Markers In vivo
Next, we analyzed the expression of bone remodeling markers 
in  vivo to address the effect of OT at the molecular level. We 
quantified mRNA expression using real-time PCR and mRNAs 
isolated from total long bones of Sham and ORX mice treated 
with vehicle or OT. We observed that orchidectomy induced a 
threefold increase of RANKL/OPG mRNA ratio, indicating an 
increase of pro-osteoclastogenic signaling. RANKL/OPG ratio 
was not affected by OT treatment and was maintained at a high 
level compared to the Sham group (Figure 3A). Regarding bone 
Figure 3 | In vivo analysis of bone molecular markers. Real-Time PCR 
for (a) RANKL, osteoprotegerin (OPG), (b) Tracp, (c) collagen 1 alpha 1 
(COL1A1), and (D) osteocalcin expression on RNA from humeri of Sham and 
ORX mice submitted to daily injections of OT or Ve for 8 weeks starting 
2 weeks after surgery (n = 12 mice/group). Data are represented as 
mean ± SEM. (a) p < 0.05 vs. Sham-Ve and (b) p < 0.05 vs. ORX-Ve.
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resorption, mRNA expression of the osteoclastogenic marker 
Tracp decreased upon orchidectomy and was normalized after 
OT treatment (Figure  3B). As expected, similar observations 
were obtained for OVX mice [data not shown (17)]. We measured 
the expression of osteoblast markers such as collagen 1 alpha 1 
(COL1A1) and osteocalcin. COL1A1 mRNA expression was not 
affected by orchidectomy but was induced by OT treatment in 
the ORX group (Figure 3C). Osteocalcin expression was induced 
upon orchidectomy and was not restored in ORX-OT mice group 
(Figure  3D). Opposite data were obtained for female mice, a 
decrease in COL1A and osteocalcin mRNA upon ovariectomy 
that were restored upon OT treatment [data not shown (17)].
Oxytocin Treatment does not normalize 
Orchidectomy-induced body Weight loss
Then, we analyzed body weight and body composition in mice 
upon OT or Ve treatment for 8 weeks. We previously observed 
Figure 1 | Micro-computed tomography of distal femur metaphysis of 
OVX and OrX mice injected or not with OT and their corresponding 
sham mice. A three-dimensional representation of a horizontal analysis of 
femurs from a representative mouse of each group is shown. Right picture 
displayed a femur radiography with the region of interest (ROI) used for 3D 
reconstruction.
Figure 2 | Plasmatic bone remodeling markers. Plasma levels of bone 
formation marker PINP (a) and bone resorption marker CTXI (b) in Sham and 
ORX mice following 8 weeks of OT or Ve treatment. Data are represented as 
mean ± SEM.  (a) p < 0.05 vs. Sham-Ve (n = 12 mice/group).
that, in OVX mice displaying an increase of both body weight 
and fat mass, OT was able to restore both parameters to levels 
of the control Sham group [data not shown (17)]. As previously 
described (21), ORX mice displayed a dramatic loss of total body 
weight (≈5 g) mainly due to a decrease in lean mass, especially in 
muscle mass, in the absence of testosterone (Figure 4). However, 
daily OT injections for 8 weeks did not restore body weight and 
muscle mass compared to Sham-Ve mice (Figure 4).
Figure 4 | effects of OT on body weight, muscle weight, and fat mass 
in OrX mice. Sham and ORX mice were submitted to daily injections of OT 
or Ve for 8 weeks starting 2 weeks after surgery. (a) Body and (b) muscle 
weights were measured at the end of treatment. (c) The volume of white 
adipose tissue between lumbar vertebra 1 (L1) and the caudal vertebra 4 (C4) 
was measured using micro-computed tomography. (D,e) Intra-abdominal and 
subcutaneous adipose tissue areas were measured on one section at the L4/
L5 (lumbar vertebra 4 and 5) junction level (n = 12 mice/group). Data are 
represented as mean ± SEM. (a) p  < 0.05 vs. Sham-Ve and (b) p < 0.05 vs. 
ORX-Ve.
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Oxytocin Treatment normalizes the increase of 
Orchidectomy-induced Fat Mass
As we showed that the OT treatment reversed ovariectomy-induced 
fat mass gain, we aimed to know whether this is also the case for 
male mice. Using micro-computed tomography, we quantified 
adipose tissue (AT) volume between the lumbar vertebra 1 (L1) and 
the caudal vertebra 4 (C4). We found a 50% increase in fat volume 
within this area in ORX compared to Sham mice (Figure 4C). 
Interestingly, we observed that OT restored the adipose tissue 
volume in ORX mice to the level of that observed in Sham-Ve 
mice, and a significant decrease of AT volume in Sham-OT treated 
mice was also observed. We next quantified the intra-abdominal 
and subcutaneous white adipose tissue (WAT) by measuring their 
respective areas on a MicroCT section at the L4/L5 junction. We 
observed that orchidectomy induced a significant increase of the 
subcutaneous WAT depot compared to the intra-abdominal depot 
(Figures 4D,E). Finally, OT treatment decreased both depots and 
more specifically restored the surface of subcutaneous WAT to 
the level observed in Sham-Ve mice. Thus, we observed that OT 
rescues the increase of the orchidectomy-induced WAT depot in a 
similar manner as that observed in female OVX mice (Figure 5).
Discussion
As for post-menopausal women or female animal models of osteo-
porosis (ovariectomized mice, OVX), severe bone loss occurs in 
men suffering from testicular dysfunction or in the corresponding 
male animal models (orchidectomized mice, ORX). Osteoporosis 
in hypogonadal men is characterized by an elevated bone turnover, 
resulting in a sustained loss of bone mass (22), which is paral-
leled by decreased muscle mass and increased fat mass (21, 23). 
Orchidectomy in male rodents induces trabecular and cortical bone 
loss, a lowered muscle mass – assessed by lean body mass – with a 
concomitant gain in fat mass (24, 25). Furthermore, as observed 
for hypogonadal men (21), testosterone treatment prevents bone 
loss and body composition changes in these rodents (25).
We and others demonstrated that OT plays a key role in the 
physiological regulation of bone, muscle, and adipose tissue (14, 
17, 19, 26). Of note, it has been established that OT pathway was 
involved in the physiology of bone remodeling for both genders 
by the analysis of OT and OTR knock-out mice (27). OT and 
OTR knock-out mice display an osteoporotic phenotype without 
any sex difference according to the authors. Using OVX mice 
as an animal model mimicking post-menopausal osteoporosis, 
we demonstrated that OT prevented and reversed osteoporosis 
in mice and also normalized body weight. The later effect was 
mainly due to a decrease in fat mass (14, 17). In this study, we 
addressed the role of OT on bone tissue and body composition 
using ORX mice, in fine to investigate if OT could be considered 
as a therapeutic treatment option for male osteoporosis at the 
expense of testosterone.
Our study demonstrates that daily injection of OT in ORX 
mice did not restore the osteoporotic phenotype. We assume that 
this difference regarding the regulation of bone remodeling and 
Figure 5 | Micro-computed tomography analysis of abdominal fat of 
OVX and OrX mice injected or not with OT and their corresponding 
sham mice. A three-dimensional representation of abdominal fat between 
lumbar vertebra 1 (L1) and sacral 1 (S1) from a representative mouse of each 
group is shown. Right pictures displayed a whole mouse radiography with the 
ROI (region of interest) used for 3D reconstruction.
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homeostasis upon gonadectomy in male and female, could be due 
to differences in the physiopathological process of osteoporosis 
induced either by testis or ovary removal. Actually, if the pheno-
typical outcome remains the same for both genders, it is known 
that the decline of the hormonal level displays some common and 
some different features depending if it occurs in male or female. 
On one hand, it is known that one of the first consequences of 
gonads removal is an increase of the osteoclastogenic potential of 
bone marrow cells leading to an increase of bone resorption (28). 
But on the other hand, if the periosteal bone formation rate is 
increased in OVX rats, there is a decrease in this periosteal bone 
formation rate in ORX rats (29).
Estrogens (i.e., estradiol) and androgens (i.e., testosterone) 
are sex steroid hormones displayed by the two genders, but with 
different levels, i.e., higher testosterone levels found in male and 
higher estradiol levels found in female. A proportion of estradiol 
originates from testosterone through its conversion by cytochrome 
p450 aromatase (30). Moreover, estradiol as well as testosterone 
treatments restored bone loss in case of hypogonadism by suppress-
ing bone resorption (31). Despite these common features, estradiol 
and testosterone do not regulate bone remodeling through the 
same cellular pathways. It has been demonstrated that testoster-
one was able to regulate bone formation and resorption activity 
through both direct and indirect inhibitory effects on osteoblasts 
and osteoclasts. By contrast, estradiol targets only osteoclast 
formation using a non-direct pathway through osteoblastic cells 
(32). We observed in our previous work that OT regulates bone 
remodeling in OVX mice through an effect on osteoblasts (14, 17). 
This observation might explain that OT can replace estrogens in 
OVX mice and rescue the osteoporotic phenotype but not in ORX 
mice for which androgens are missing. However, estrogens are able 
to rescue the osteoporotic phenotype of ORX mice (33) whereas 
OT that can substitute for estrogen in OVX mice is unable to do 
so in male mice. This last discrepancy could be explained by the 
fact that OT and its receptor are regulated by estrogens and thus 
are located downstream in the estrogen signaling pathway. As a 
whole, these observations may lead to understand why OT can 
compensate for the estrogen defect in OVX regarding the bone 
phenotype whereas it is inefficient in the case of ORX mice that 
are lacking testosterone.
Androgens may not only impact muscle size or weight but also 
functional aspects such as muscle fiber type composition. In this 
way, testosterone treatment promotes lean mass as well as myofiber 
hypertrophy (34), and prevents the orchidectomy-induced shift of 
type I slow oxidative toward type IIa fast oxidative muscle fibers 
in slow muscle (35). Thus, testosterone regulates both the mass 
and function of skeletal muscle in adults. OT plasma levels and 
muscle stem cells OTR levels dramatically decline with age and 
demonstrate that OT is required for skeletal muscle tissue regen-
eration and homeostatic maintenance (19). In this recent work, 
Elabd and collaborators showed that acute OT treatment restored 
muscle regeneration in old mice, while OT signaling attenuation 
altered muscle regeneration in young mice (19). This effect seems 
to be triggered directly through muscle stem cell function. In other 
words, old mice deficient for OT displayed sarcopenia features. It 
is interesting to note that muscle mass declines with age in OT 
knock-out mice. The resistance of young mice could be related to 
high-testosterone levels, and the phenotype may be associated to 
the decrease in testosterone levels found in older mice (19). In 
our study, ORX mice displayed an expected loss of muscle mass, 
which was not rescued by OT treatment. This could be due to 
the interrelation between OT and testosterone pathways and can 
explain the inability of OT to rescue muscle mass decrease in ORX 
mice where testosterone level is very low.
In contrast to bone and muscle, OT treatment reversed 
orchidectomy-induced fat gain. It is accepted that hypogonadism 
induces adiposity in male, but the specific relation with visceral 
(intra-abdominal) adiposity is less documented compared to 
female mice (36). Indeed, visceral adiposity is a well-known risk 
factor for hypogonadism in male, due to the fact that this tissue 
is a key location for conversion of testosterone into estradiol, but 
the direct involvement of androgens on visceral fat development is 
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not clear yet (37). Under physiological conditions, visceral  adipose 
tissue mass is two times higher in male compared to female, 
independently of hypogonadism but correlated with physiological 
levels of estradiol (38). After menopause, and not andropause, this 
visceral fat mass increases dramatically (38). These data clearly 
link estrogens, and not androgens, to the development of this 
adipose tissue. OT treatment induces a decrease in subcutaneous 
and intra-abdominal adipose tissue of OVX and ORX mice, with 
a higher effect on intra-abdominal adipose tissue in female due to 
the fact that this tissue is specifically impacted after ovariectomy. 
Thus, it is tempting to hypothesize that this OT effect is mediated 
via an estrogen dependent pathway.
In conclusion, our present work associated with our previous 
published studies, demonstrated that OT is able to reverse features 
of hypogonadism directly related to estrogen pathway, but OT is 
not able to compensate the decline in androgen levels. OT seems 
to be an interesting alternative to estrogens treatment in post-
menopausal women, and due to its important function in 
adiposity and in muscle regeneration, OT could be proposed in 
association with efficient testosterone treatment in men upon 
hypogonadism. Moreover, this kind of associated treatment 
could be very interesting in men displaying a defect in estrogen 
synthesis due to aromatase activity deficiency (39).
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